GAITHERSBURG, Md., May 31 /PRNewswire/ -- Panacea Pharmaceuticals, Inc.
announced today that PC Detect(sm), the Company's prostate cancer screening
test, is now available from Panacea Laboratories. PC Detect(sm) is a simple
blood test, which is recommended as an adjunct to the prostate specific
antigen (PSA) test and the digital rectal examination (DRE), the currently
recommended prostate cancer screening methods. The addition of PC
Detect(sm) to the current screening methods is expected to improve the
diagnosis of prostate cancer among men with prostate specific antigen (PSA)
values below the currently recommended level for prostate biopsy. Panacea
Laboratories, a division of Panacea Pharmaceuticals, is certified under the
Clinical Laboratory Improvement Amendments of 1988 (CLIA). The blood sample
can be ordered by any physician and sent to Panacea for testing; sample and
shipping requirements are available at http://www.panacea-labs.com. The
Company anticipates submission of a Pre-Market Application (PMA) to the
U.S. Food and Drug Administration later in 2007 to facilitate development
of a PC Detect(sm) kit, which will be commercialized through clinical
laboratories around the country.
Prostate cancer is currently the most prevalent form of cancer in men
and the second leading cause of male cancer deaths in the United States.
The standard-of-care screening tools for prostate cancer used by physicians
to determine whether to refer a patient for a prostate biopsy include the
prostate-specific antigen (PSA) and the digital rectal examination (DRE).
The American Cancer Society (ACS) recommends that a PSA blood test and DRE
be performed annually in men > 50 years old. However, the predictive value
of an elevated PSA and/or an abnormal DRE is limited. PSA is a
tissue-specific protein and has been shown to be elevated in patients with
benign prostatic conditions as well as in patients with prostate cancer.
About 25% of men recommended for prostate biopsy with a PSA of 4-10 ng/mL
will be found to have cancer on biopsy, and a PSA > 4.0 ng/mL has a
sensitivity of 46% for identification of patients who will be found to have
prostate cancer over the next 10 years. According to the ACS, patients with
a PSA > 10 ng/mL should undergo a prostate biopsy since >50% of these men
are likely to have cancer.
However, men with PSA levels of 2-4 ng/mL are not routinely recommended
to have prostate biopsies, despite the fact that almost 24% of men with PSA
levels of 2.1 to 3.0 ng/mL will be diagnosed with prostate cancer as will
almost 27% of men with PSA levels of 3.1 to 4.0 ng/mL, according to a study
by Thompson et.al., published in 2004 in the New England Journal of
Medicine. PC Detect(sm) has demonstrated a sensitivity of greater than 90%
in identifying men with prostate cancer who have PSA levels of 2-4 ng/mL.
Punglia et.al. (2003) found that if prostate biopsies were performed only
when the PSA level is greater than 4.0 ng/mL, 82% of cancers would be
missed in those who are younger than 60 years of age, and 65% would be
missed in those who are 60 or older. As such, PC Detect(sm) may aid in the
identification of a significant number of men with prostate cancer at an
earlier stage and facilitate improved outcomes.
PC Detect(sm), a CLIA laboratory service, is a new method for screening
a patient's serum to help determine the likelihood that prostate cancer is
present. PC Detect(sm) provides information to differentiate prostate
cancer from benign conditions and to help guide both the physician and the
patient regarding further diagnostic testing and management by measuring
blood levels of Human Aspartyl (Asparaginyl) beta-Hydroxylase (HAAH), a
cancer biomarker. HAAH has been established as an excellent biomarker for
many types of cancer, including prostate cancer. The protein is typically
undetectable in sera from cancer-free individuals, thus, an elevated serum
protein level of HAAH is highly diagnostic for cancer.
"The addition of PC Detect(sm) to standard-of-care prostate cancer
screening, with PSA and DRE, should significantly enhance a physician's
ability to identify men at high-risk of having prostate cancer, even in
those with PSA levels of 2-4 ng/mL," commented Pamela Jo Harris, MD, Vice
President, Medical and Clinical Affairs at Panacea. "We are confident that
the addition of PC Detect(sm) will help internists, family practitioners,
and urologists better assess the need for a patient to have a prostate
biopsy and to identify those likely to have prostate cancer."
About Panacea's Oncology Platform
In addition to PC Detect(sm), Panacea offers, TK Sense(sm), which
determines whether white blood cells from patients with chronic myelogenous
leukemia (CML) are sensitive or resistant to imatinib, the therapy of first
choice for CML patients, prior to initiation of therapy.
The HAAH serum assay will be further developed as a diagnostic test for
other types of cancer. Panacea is also pursuing the development of
antibodies directed against human aspartyl (asparaginyl) beta-hydroxylase
(HAAH) as novel agents for the treatment of cancer with liver cancer as its
first therapeutic indication. The Company is exploring both naked anti-HAAH
antibodies as well as HAAH antibodies conjugated to chemotherapeutic agents
and toxins.
About Panacea Pharmaceuticals, Inc.
Panacea Pharmaceuticals, Inc. is a privately-held biopharmaceutical
company focused on the development and commercialization of therapeutics
and diagnostics for diseases with substantial, unmet clinical needs. The
Company's product development strategy is based on novel therapeutic agents
and approaches for cancer treatment, as well as acute and chronic
neurodegenerative conditions, such as hypoxia-induced neurological insult,
Parkinson's Disease, and Alzheimer's Disease. Panacea has an extensive
patent portfolio covering its neurodegenerative and oncology technologies.
Panacea Laboratories is a division of Panacea Pharmaceuticals, Inc.
More information about the Company is available at
http://www.PanaceaPharma.com.
Except for historical information presented in this press release,
matters discussed herein may constitute "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995.
Forward- looking statements are based on the opinions and estimates of
management only as of the date of this release and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from any future results, performance, or achievements expressed
or implied by such statements. Factors that might cause such a difference
include, but are not limited to, uncertainties related to our access to
capital, the progress, costs, and results of any clinical trials undertaken
by us, progress of our research and development projects, and uncertainties
related to whether our product candidates would ultimately achieve
commercial success. We do not undertake any obligation to update publicly
any forward-looking statement, whether as a result of new information,
future events, or otherwise unless required by law.
SOURCE Panacea Pharmaceuticals, Inc.
 back to top
Related links:
http://www.panaceapharma.com
http://www.panacea-labs.com
CONTACT:
Stephen N. Keith, MD, MSPH, President & COO
of Panacea Pharmaceuticals, Inc., +1-240-243-8000, Fax
+1-240-465-0450, skeith@panaceapharma.com
|
